| Literature DB >> 33419159 |
Nicholas Meti1, Houman Tahmasebi1, Angela Leahey2, Angela Boudreau2, Alia Thawer3, Janice Stewart2, Paige Reason2, Kirsty Albright2, Jerome A Leis1,4, Kevin Katz1,5, Matthew C Cheung1,2, Simron Singh1,2.
Abstract
Patients with cancer are more vulnerable to severe COVID-19. As a result, routine SARS-CoV-2 testing of asymptomatic patients with cancer is recommended prior to treatment. However, there is limited evidence of its clinical usefulness. The objective of this study is to evaluate the value of routine testing of asymptomatic patients with cancer. Asymptomatic patients with cancer attending Odette Cancer Centre (Toronto, ON, Canada) were tested for SARS-CoV-2 prior to and during treatment cycles. Results were compared to positivity rates of SARS-CoV-2 locally and provincially. All 890 asymptomatic patients tested negative. Positivity rates in the province were 1.5%, in hospital were 1.0%, and among OCC's symptomatic cancer patients were 0% over the study period. Given our findings and the low SARS-CoV-2 community positivity rates, we recommend a dynamic testing model of asymptomatic patients that triggers testing during increasing community positivity rates of SARS-CoV-2.Entities:
Mesh：
Year: 2021 PMID： 33419159 PMCID： PMC7903264 DOI： 10.3390/curroncol28010032
Source DB: PubMed Journal: Curr Oncol ISSN： 1198-0052 Impact factor: 3.677